Cargando…
Weighing up the evidence used by direct-to-consumer stem cell businesses
Hundreds of businesses across the United States offer direct-to-consumer stem-cell-based interventions that have not been approved by the Food and Drug Administration. Here, we characterize the types of evidence used on the websites of 59 stem cell businesses in the Southwest United States to market...
Autores principales: | Cook, Margaret, Richey, Alexandra, Brafman, David A., Frow, Emma K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693621/ https://www.ncbi.nlm.nih.gov/pubmed/34767748 http://dx.doi.org/10.1016/j.stemcr.2021.10.007 |
Ejemplares similares
-
Characterizing Direct-to-Consumer Stem Cell Businesses in the Southwest United States
por: Frow, Emma K., et al.
Publicado: (2019) -
Atrial fibrillation in obesity: Weighing up the evidence for catheter ablation
por: Javed, Saad, et al.
Publicado: (2020) -
Perceived fairness of direct-to-consumer genetic testing business models
por: Toussaint, Philipp A., et al.
Publicado: (2022) -
Physicists weigh up new budget reality
por: Gwynne, P
Publicado: (2001) -
Weighing up a seven-year period
por: Chiesa, Fausto
Publicado: (2011)